Christopher Westland

2.3k total citations
26 papers, 1.6k citations indexed

About

Christopher Westland is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Christopher Westland has authored 26 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Epidemiology, 16 papers in Hepatology and 12 papers in Infectious Diseases. Recurrent topics in Christopher Westland's work include Hepatitis C virus research (16 papers), Hepatitis B Virus Studies (14 papers) and HIV/AIDS drug development and treatment (12 papers). Christopher Westland is often cited by papers focused on Hepatitis C virus research (16 papers), Hepatitis B Virus Studies (14 papers) and HIV/AIDS drug development and treatment (12 papers). Christopher Westland collaborates with scholars based in United States, France and Belgium. Christopher Westland's co-authors include Craig S. Gibbs, Huiling Yang, Shelly Xiong, Kalyan Das, Eddy Arnold, William E. Delaney, Carol Brosgart, John Fry, Stefan G. Sarafianos and Xiao‐Feng Xiong and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Christopher Westland

24 papers receiving 1.5k citations

Peers

Christopher Westland
Urania Georgopoulou Greece
Richard R. Lesniewski United States
Marie-Anne Petit France
Brian E. Nolan United States
Helenia Ansuini Italy
Vicky M.-H. Sung United States
Axel Ulsenheimer Germany
Kazunori Kajino Japan
Doris Quinkert United Kingdom
Daisuke Akazawa Japan
Urania Georgopoulou Greece
Christopher Westland
Citations per year, relative to Christopher Westland Christopher Westland (= 1×) peers Urania Georgopoulou

Countries citing papers authored by Christopher Westland

Since Specialization
Citations

This map shows the geographic impact of Christopher Westland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Westland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Westland more than expected).

Fields of papers citing papers by Christopher Westland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Westland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Westland. The network helps show where Christopher Westland may publish in the future.

Co-authorship network of co-authors of Christopher Westland

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Westland. A scholar is included among the top collaborators of Christopher Westland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Westland. Christopher Westland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hou, Jinlin, Junqi Niu, Xieer Liang, et al.. (2023). Treatment for up to 24 weeks with the capsid assembly modulator ALG-000184 results in dose related reductions in HBsAg in subjects with HBeAg positive chronic hepatitis B. Journal of Hepatology. 78. S1164–S1165. 1 indexed citations
3.
Yuen, Man‐Fung, Kosh Agarwal, Edward Gane, et al.. (2022). Safety, pharmacokinetics, and antiviral activity of the class II capsid assembly modulator ALG-000184 in subjects with chronic hepatitis B. Journal of Hepatology. 77. S835–S836. 8 indexed citations
4.
Gane, Edward, Kosh Agarwal, Man‐Fung Yuen, et al.. (2022). Safety, pharmacokinetics, and antiviral activity of the S-antigen Transport Inhibiting Oligonucleotide Polymers (STOPS) drug candidate ALG-010133 in subjects with chronic hepatitis B. Journal of Hepatology. 77. S871–S872. 1 indexed citations
5.
Kakuda, Thomas N., Jeysen Yogaratnam, Christopher Westland, et al.. (2019). FRI-180-JNJ-64530440, a novel capsid assembly modulator: single- and multiple-ascending dose safety, tolerability and pharmacokinetics in healthy volunteers. Journal of Hepatology. 70(1). e469–e469. 7 indexed citations
6.
McClure, Matthew W., Elina Berliba, Tengiz Tsertsvadze, et al.. (2018). Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects. PLoS ONE. 13(10). e0204974–e0204974. 8 indexed citations
7.
Valade, Elodie, Thomas N. Kakuda, Matthew W. McClure, et al.. (2018). Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir. The AAPS Journal. 21(1). 1–1. 10 indexed citations
8.
DeVincenzo, John P., Matthew W. McClure, Julian Symons, et al.. (2015). Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study. New England Journal of Medicine. 373(21). 2048–2058. 164 indexed citations
9.
DeVincenzo, John P., Hosnieh Fathi, Matthew W. McClure, et al.. (2014). LB-1Treatment with Oral ALS-008176, a Nucleoside Analog, Rapidly Reduces RSV Viral Load and Clinical Disease Severity in a Healthy Volunteer Challenge Study. Open Forum Infectious Diseases. 1(suppl_1). S66–S66. 13 indexed citations
10.
Lonial, Sagar, Ravi Vij, Jean‐Luc Harousseau, et al.. (2012). Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology. 30(16). 1953–1959. 236 indexed citations
11.
Westland, Christopher, Huiling Yang, William E. Delaney, et al.. (2003). Week 48 Resistance Surveillance in Two Phase 3 Clinical Studies of Adefovir Dipivoxil for Chronic Hepatitis B. Hepatology. 38(1). 96–103. 120 indexed citations
12.
Villeneuve, Jean‐Pierre, David Durantel, S. Durantel, et al.. (2003). Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. Journal of Hepatology. 39(6). 1085–1089. 236 indexed citations
13.
Yang, Huiling, Christopher Westland, William E. Delaney, et al.. (2002). Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology. 36(2). 464–473. 132 indexed citations
14.
Westland, Christopher, William E. Delaney, John Fry, et al.. (2002). Distribution and clinical response of HBV genotypes in phase III studies of adefovir dipivoxil. Journal of Hepatology. 36. 105–105. 4 indexed citations
15.
Yang, Huiling, Christopher Westland, William E. Delaney, et al.. (2002). Lack of emerging resistance mutations in 467 HBeAg− and HBeAg+ patients with chronic hepatitis B receiving Adefovir Dipivoxil for 48 weeks. Journal of Hepatology. 36. 137–138. 1 indexed citations
16.
Das, Kalyan, Xiao‐Feng Xiong, Huiling Yang, et al.. (2001). Molecular Modeling and Biochemical Characterization Reveal the Mechanism of Hepatitis B Virus Polymerase Resistance to Lamivudine (3TC) and Emtricitabine (FTC). Journal of Virology. 75(10). 4771–4779. 220 indexed citations
17.
Xiong, Xiaofeng, Huiling Yang, Christopher Westland, Ruiming Zou, & Craig S. Gibbs. (2000). In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology. 31(1). 219–224. 61 indexed citations
18.
Buttini, Manuel, et al.. (1998). Novel role of human CD4 molecule identified in neurodegeneration. Nature Medicine. 4(4). 441–446. 26 indexed citations
19.
D’Hooge, Rudi, Guy Nagels, Christopher Westland, Lennart Mucke, & Peter Paul De Deyn. (1996). Spatial learning deficit in mice expressing human 751-amino acid β-amyloid precursor protein. Neuroreport. 7(15). 2807–2812. 51 indexed citations
20.
Housel, Thomas J., et al.. (1993). Business process reengineering at Pacific Bell. Planning Review. 21(3). 28–33. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Urania Georgopoulou Breakdown of academic impact, for papers by Richard R. Lesniewski Breakdown of academic impact, for papers by Marie-Anne Petit Breakdown of academic impact, for papers by Brian E. Nolan Breakdown of academic impact, for papers by Helenia Ansuini Breakdown of academic impact, for papers by Vicky M.-H. Sung Breakdown of academic impact, for papers by Axel Ulsenheimer Breakdown of academic impact, for papers by Kazunori Kajino Breakdown of academic impact, for papers by Doris Quinkert Breakdown of academic impact, for papers by Daisuke Akazawa
Rankless by CCL
2026